Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
14
drug-resistant BTK variantsWording
Conditional
How definitive the wording is.Announced details
docirbrutinib (AS-1763)
Applicable field (uses covered by this announcement)
B-cell malignanciesChronic lymphocytic leukemia (CLL)Small lymphocytic lymphoma (SLL)Blood cancers
What the company reported numerically
Quantitative Effects
Potent inhibition of all BTK proteins with 14 drug-resistant mutations
Strong combination effects with venetoclax and AZD5991
Relationship between the counterparty and the company
Carna Biosciences,Inc.4572
Relationship with the Company
Joint research conducted.
CounterpartyThe University of Texas MD Anderson Cancer Center
A cancer research and treatment institution located in Houston, Texas, USA.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
Blood Cancer Journal
Springer Nature
| Item | Details |
|---|---|
| Names of Products / Services Covered | docirbrutinib (AS-1763) |
| Counterparty | The University of Texas MD Anderson Cancer Center |
| Counterparty overview | A cancer research and treatment institution located in Houston, Texas, USA. |
| Relationship with the Company | Joint research conducted. |
| Applicable area | B-cell malignancies, Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Blood cancers |
| Quantitative Effects | Potent inhibition of all BTK proteins with 14 drug-resistant mutations, Strong combination effects with venetoclax and AZD5991 |
| Source | Blood Cancer Journal, Springer Nature |
Items this document does not state (11)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To address the issue of drug-resistant mutations arising with existing BTK inhibitors.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.